Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.8 EUR | +0.13% | +1.84% | -1.02% |
06-03 | Orion Partners with Universities for Biotechnology Project in Finland | MT |
05-07 | Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
Weaknesses
- The firm trades with high earnings multiples: 22.63 times its 2024 earnings per share.
- The company's enterprise value to sales, at 3.94 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.02% | 5.91B | - | ||
+45.82% | 765B | C+ | ||
+40.95% | 632B | B | ||
-6.16% | 354B | C+ | ||
+19.86% | 331B | B- | ||
+9.32% | 299B | C+ | ||
+18.45% | 248B | B+ | ||
-0.78% | 219B | A+ | ||
+11.88% | 216B | B- | ||
+5.90% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ORNBV Stock
- ORNAV Stock
- Ratings Orion Oyj